HK Stock Market Move | INNOGEN-B(02591) rose more than 4% as its core product, Elesupagrulide , officially entered the commercial sales stage in Macau.

16/09/2025

Yinnuo Pharmaceuticals-B (02591) rose more than 4%, as of press time, up 4.42% to HKD 46.3, with a turnover of HKD 125.852 million.

INNOGEN-B(02591) surged over 4%, as of the time of writing, it rose 4.42% to 46.3 Hong Kong dollars, with a turnover of 12.5852 million Hong Kong dollars. On the news front, INNOGEN-B announced that the company has been actively promoting the global expansion of its core product (Isupaglucose ) and received approval in June 2025 from the Macao Special Administrative Region of the People's Republic of China to treat type 2 diabetes (T2D) with the core product's Biologics License Application (BLA). The company's board of directors happily announced that on September 12, 2025, the first prescription for the core product for the treatment of type 2 diabetes has been issued at the Macao Huabo Medical Center, marking the official entry of the core product into the commercial sales stage in Macao.

HK Stock Market Move | BIOCYTOGEN-B(02135) rose more than 7% in the afternoon and reached a licensing deal with Tubulis again. The company had reached a collaboration with Merck at the beginning of the month.

HK Stock Market Move | Liaoning Port (02880) rose more than 10%. Dalian Port's holding plan has been fully implemented, and the company's performance in the first half of the year has seen a substantial increase.

China International: Maintain CHEERWIN GP (06601) with a "buy" rating, target price of 3 Hong Kong dollars.